

Hydrogenolytic Transformations of 5a,11a-Epoxyhexahydronaphthacene-5,6,11,12-tetrone. Implications for the Synthesis of 6- and 11-Deoxyanthracyclinones

Peter N. Preston,^a Thomas Winwick,^a and John O. Morley^b


^a Department of Chemistry, Heriot-Watt University, Riccarton, Currie, Edinburgh EH14 4AS, U.K.

^b I.C.I. plc, Organics Division, Blackley, Manchester M9 3DA, U.K.

Catalytic hydrogenation (H_2 , Pd-C) of the epoxide (**5a**) gives the dione derivative (**6**); an analogous procedure (**5d**)→(**7**) has been used in a sequence (**5b**)→(**5c**)→(**5d**)→(**7**)→(**2d**)→(**2b**) to give a valuable intermediate (**2b**) for the synthesis of 4,11-dideoxyanthracyclinones: implications for interconversions in the anthracyclinone series are described.


There is considerable interest in the total synthesis of the anthracyclinone derivative, adriamycin (**1a**)¹ and in related compounds such as 4-demethoxy- (**1b**),² 11-deoxy- (**1c**),³ and 6-deoxy-adriamycin (**1d**). The preparation of intermediates (**2a,b**) relating to 4,6-⁴ and 4,11-dideoxyanthracyclinones⁵ has recently been achieved in a DC→DCBA Diels-Alder approach using naphthoquinone and ring A 1,3-diene synthons.

Our synthetic approach to 6- and/or 11-deoxyanthracyclinone intermediates [cf. (**2a,b**)] is based on an overall transformation [(**2c**) (equivalent)→(**2a**) and/or (**2b**)] and is modelled on the known hydrogenolysis-oxidation sequence (**3a**)→(**4**)→(**3b**)⁶ recently elaborated in our studies.⁷




(1; X = daunosaminyI)

	R ¹	R ²	R ³
a;	OMe	OH	OH
b;	H	OH	OH
c;	OMe	OH	H
d;	OMe	H	OH




(2)

	R ¹	R ²	RR
a;	OH	H	=O
b;	H	OH	=O
c;	OH	OH	=O
d;	H	OH	-O[CH ₂] ₂ O-



(3)


	R ¹	R ²
a;	OH	OH
b;	OH	H




(4)

Compounds related to (**2c**) are available from epoxy tetrone† [cf. (**5**)] and the latter were selected as (**2c**) equivalents suitable for hydrogenolysis. Thus the model compound (**5a**) was reduced catalytically [H_2 (40 atm.), 5% Pd-C, HCONMe₂, 80 °C, 15 h] and after work-up in air gave directly (**6**)‡ (m.p. 242–244 °C, 51%). In the series relating to (**2a**) and/or (**2b**) synthesis, the sequence (**5b**)→(**5c**)→(**5d**)→(**7**)→(**2d**)→(**2b**) was successfully accomplished.§





The regiochemical outcome of the hydrogenolysis step¶ (**5d**)→(**7**) could not be ascertained from spectral data but became clear from subsequent conversion (**7**)→(**2d**)→(**2b**) into a product (**2b**) of known structure.



(5)



(6)



(7)

† Regioselective annulation of 1,3-dienes to quinizarin quinone can be effected by protection of the 4a,9a-double bond as the epoxide (see ref. 8).

‡ Satisfactory analytical and spectral data were obtained for all new compounds.

§ (**5b**) (90%, m.p. 205–207 °C) was prepared by a modification of the method of ref. 8 using CH₂=C(OSiMe₃)CH=CH₂, CH₂Cl₂, 25 °C, 3 days. (**5c**) [96%, m.p. 200–220 °C (dec.)] was prepared from (**5b**), 7% HCl, tetrahydrofuran, 0.5 h, 25 °C. (**5d**) [78% m.p. 185–200 °C (dec.)] was prepared from (**5c**), HO[CH₂]₂OH, *p*-MeC₆H₄SO₃H, CH₂Cl₂, 40 °C, 2 h. (**7**) (28%, m.p. 186–188 °C) was prepared from (**5d**), H₂ (40 atm.), 5% Pd-C, HCONMe₂, 80 °C, 15 h. (**2d**) (85%, m.p. 255–227 °C) was prepared from (**7**), K₂CO₃, MeOH, 65 °C, 0.5 h. (**2b**) (92%) was prepared from (**2d**), 36% HCl, tetrahydrofuran, 68 °C, 0.5 h. The sample of (**2b**) was identical (m.p., i.r., n.m.r., u.v.) with an authentic sample.

¶ The hydrogenolysis product from (**5d**) is complex and (**7**) could only be isolated in 28% yield. It is unlikely that this process is regioselective.

In addition to providing an inexpensive route to 4,11-dideoxyanthracyclinone intermediates, these results provide encouragement to extend hydrogenolyses of this type to epoxide intermediates in the 4-methoxy-6,11-dihydroxy series, and ultimately, to effect the direct interconversion of suitably protected 6,11-dihydroxyanthracyclines into 6- and/or 11-deoxy analogues.

We thank the SERC for a CASE award (to T. W.), Dr. S. G. Will for helpful suggestions, and Professor J. P. Gesson for generously providing samples of (2a) and (2b).

Received, 2nd December 1983; Com. 1571

References

1 F. Arcamone, 'Doxorubicin: Anticancer Antibiotics,' Academic Press, New York, 1981; T. R. Kelly, *Annu. Rep. Med. Chem.*,

1979, **14**, 288; 'Anthracycline Antibiotics,' ed. H. S. El Khadem, Academic Press, New York, 1982.

2 F. Arcamone, L. Bernadi, P. Giardino, and A. Di Marco, German Patent 2,652,391, 1977; *Chem. Abstr.*, **87**, 152522.

3 F. Arcamone, G. Cassinelli, F. Di Matteo, S. Forenza, M. C. Ripamonte, G. Rivola, A. Vigevani, J. Clardy, and T. McCabe, *J. Am. Chem. Soc.*, 1980, **102**, 1462.

4 J. P. Gesson, J. C. Jacquesy, and M. Mondon, *Tetrahedron Lett.*, 1981, **22**, 1337.

5 J. P. Gesson, J. C. Jacquesy, and M. Mondon, *Tetrahedron Lett.*, 1980, **21**, 3351.

6 K. Zahn and H. Koch, *Ber.*, 1938, **71**, 172.

7 P. N. Preston, S. G. Will, T. Winwick, and J. O. Morley, *J. Chem. Soc., Perkin Trans. 1*, 1983, 1001.

8 M. Chandler and R. J. Stoodley, *J. Chem. Soc., Perkin Trans. 1*, 1980, 1007.
